It now seems so long ago that Pfizer ( PFE +0.31% ) became the first company in the biopharmaceutical industry to generate over $100 billion in annual sales. The drugmaker achieved this milestone thanks to its dominance in the coronavirus vaccine market. However, this niche has since shrunk considerably -- and it could become even smaller next year. Regulators in the U.S. are making it harder for healthy individuals to get vaccinated.

Pfizer needs a way to replace this dwindling franchise, but so far, it has had little luck. Could the company make progress toward that goal next year? What should we expect from Pfizer in 2026?

Another mRNA vaccine in the works

Pfizer's Comirnaty is an mRNA-based COVID vaccine and became the first such candidate to earn approval from the U.S. Food

See Full Page